A 52-Week, Open-Label Study Evaluating the Safety and Efficacy of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, for Rheumatoid Arthritis
Arthritis Research and Therapy - United Kingdom
doi 10.1186/s13075-014-0415-2
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2014
Authors
Publisher
Springer Science and Business Media LLC